Red Light Holland Corp.
TRUFF • Drug Manufacturers - Specialty & Generic
$0.02
— 0.00 (0.00%)
Current price
EarningsLatest report: Dec 31, 2025
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$8.77M
Growth
-38.3%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 119.6%Manageable debt level · 0.13Healthy liquidity · 4.53Weak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Mar 2, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.02
Change0.00%
Shares Out417.59M
Market Cap$8.77M
52W Range0.01 - 0.05
Beta0.93
P/E-1.27
P/S5.54
P/B0.48
P/FCF-8.71
EV/Sales0.47
EV/EBITDA-0.54
Price$0.02
Change0.00%
Shares Out417.59M
Market Cap$8.77M
52W Range0.01 - 0.05
Beta0.93
P/E-1.27
P/S5.54
P/B0.48
P/FCF-8.71
EV/Sales0.47
EV/EBITDA-0.54
EV/FCF-0.75
Earnings Yield-19.69%
FCF Yield-11.48%
Dividend Yield0.00%
Gross Margin38.69%
Oper. Margin-85.15%
Profit Margin-81.75%
Debt/Eq0.13
Current Ratio4.53
Quick Ratio4.22
Revenue 5Y-38.28%
Volume10.01K
Avg Volume280.55K
Investment DNA
How strong this company looks for long-term investors
55
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
88/100
Why this score▼
Positive revenue growth · 119.6%Manageable debt level · 0.13Healthy liquidity · 4.53Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.